drugset / Trial / NCT04887506
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.
Timeline
- Start
- 2021-05-05
- Primary completion
- 2022-10-20
- Completion
- 2022-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | abiraterone acetate | Small molecule | 250 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |